Cited by 1,023Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins

Open access

Borchelt, David R, Ratovitski, Tamara, van Lare, Judy, Lee, Michael K, Gonzales, Vicki, Jenkins, Nancy A, Copeland, Neal G, Price, Donald L, Sisodia, Sangram S·1997·Neuron

DOI 10.1016/s0896-6273(00)80974-5

Open this paper in CoChat — free account

Abstract

Missense mutations in two related genes, termed presenilin 1 (PS1) and presenilin 2 (PS2), cause dementia in a subset of early-onset familial Alzheimer's disease (FAD) pedigrees. In a variety of experimental in vitro and in vivo settings, FAD-linked presenilin variants influence the processing of the amyloid precursor protein (APP), leading to elevated levels of the highly fibrillogenic Abeta1-42 peptides that are preferentially deposited in the brains of Alzheimer Disease (AD) patients. In this report, we demonstrate that transgenic animals that coexpress a FAD-linked human PS1 variant (A246E) and a chimeric mouse/human APP harboring mutations linked to Swedish FAD kindreds (APP swe) develop numerous amyloid deposits much earlier than age-matched mice expressing APP swe and wild-type Hu PS1 or APP swe alone. These results provide evidence for the view that one pathogenic mechanism by which FAD-linked mutant PS1 causes AD is to accelerate the rate of beta-amyloid deposition in brain.

Integrity signals

Registry

Crossref · 10.1016/s0896-6273(00)80974-5

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

Familial Alzheimer's disease associated with S182 codon 286 mutation
Chapman, J., Asherov, A., Wang, N., Treves, T. A., Korczyn, A. D., & Goldfarb, L. G. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91723-3 · Cited by 25
Retracted
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Self-citation
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Self-citation
Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022

Show all 52 references

Research works printed but not linked: 2

Barelli, 1997, Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid β peptides, Mol. Med, in press
Kim, 1990, Detection and quantitation of amyloid β-peptide with 2 monoclonal antibodies, Neurosci. Res. Commun, 7, 113

Sorted by citations

Items 801–900 of 1,000

Cholinergic Neurons of the Rodent Basal Forebrain and Their Content of Estrogen Receptor Alpha
Kalesnykas, G. (2005) · Cited by 8
Aging of the Brain and Alzheimer’s Disease
Price, D. L., Savonenko, A. V., Albert, M., Troncoso, J. C., & Wong, P. C. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.00539-8 · Cited by 8
Self-citation
Fibrinogen-Derived γ377–395 Peptide Improves Cognitive Performance and Reduces Amyloid-β Deposition, without Altering Inflammation, in AβPP/PS1 Mice
Aso, E., Serrano, A. L., Muñoz‐Cánoves, P., & Ferrer, I. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142928 · Cited by 7
Reserpine Improves Working Memory
Vasantharaja, R., Kumar, A., Kumar, A., & Subramaniam, J. R. (2016) · Journal of Behavioral and Brain Science · doi:10.4236/jbbs.2016.63012 · Cited by 7
Genetic dissection of neurodegenerative disease
Hardy, J. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(00)00013-x · Cited by 7
Responses of Cultured Astrocytes, C6 Glioma and 1321NI Astrocytoma Cells to Amyloid β-Peptide Fragments
Pentreath, V. W., & Mead, C. (2004) · Nonlinearity in Biology Toxicology Medicine · doi:10.1080/15401420490426990 · Cited by 7
The age-related slow increase in amyloid pathology in APP.V717I mice activates microglia, but does not alter hippocampal neurogenesis
Hoeijmakers, L., Meerhoff, G. F., de Vries, J. W., Ruigrok, S. R., van Dam, A., LEUVEN, F. V., Kőrösi, A., & Lucassen, P. J. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.013 · Cited by 7
A Generic Research Paradigm for Identification and Validation of Early Molecular Diagnostics and New Therapeutics in Common Disorders
Coon, K. D., Dunckley, T. L., & Stephan, D. A. (2007) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256218 · Cited by 7
Timing impairments in early Alzheimer’s disease: Evidence from a mouse model.
Armstrong, P., Pardon, M., & Bonardi, C. (2020) · Behavioral Neuroscience · doi:10.1037/bne0000359 · Cited by 7
Cholinergic Neurodegeneration in Alzheimer's Disease: Basis for Nerve Growth Factor Therapy
Salehi, A., Kleschevnikov, A. M., & Mobley, W. C. (2007) · Springer eBooks · doi:10.1007/978-0-387-71522-3_5 · Cited by 7
Braak Staging in Mouse Models of Alzheimer's Disease
Granic, I., Masman, M. F., Luiten, P. G. M., & Eisel, U. L. M. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100656 · Cited by 7
Mechanism of Neuronal Death in Alzheimer’s Disease
Irizarry, M. C. (2002) · Advances in behavioral biology · doi:10.1007/978-0-306-47593-1_23 · Cited by 7
Alzheimer’s disease: transgenic mouse models and drug assessment
Yu, P., & Oberto, G. (2000) · Pharmacological Research · doi:10.1006/phrs.2000.0670 · Cited by 7
Cholinergic Neurotransmission, Amyloid-β Peptide and the Pathogenesis of Alzheimer's Disease
Liu, L. (2003) · Cited by 7
Proteome characterization of splenocytes from an A β pp/ps‐ 1 Alzheimer's disease model
Cao, Z., & Robinson, R. A. S. (2013) · PROTEOMICS · doi:10.1002/pmic.201300130 · Cited by 6
Oxidative Stress in CD90+ T-cells of AβPP/PS-1 Transgenic Mice
Robinson, R. A. S., Cao, Z., & Williams, C. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130665 · Cited by 6
Links Between Amyloid and Tau Biology in Alzheimer’s Disease and Their Cholinergic Aspects
Siegel, G. J., Chauhan, N. B., & Karczma, A. G. (2007) · Springer eBooks · doi:10.1007/978-0-387-46526-5_10 · Cited by 6
Evoked Cortical Depolarizations Before and After the Amyloid Plaque Accumulation: Voltage Imaging Study
Zhu, M. H., Jogdand, A. H., Jang, J., Nagella, S. C., Das, B., Milosevic, M. M., Yan, R., & Antic, S. D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220249 · Cited by 6
Early Changes in Behavior Deficits, Amyloid β-42 Deposits and MAPK Activation in Doubly Transgenic Mice Co-expressing NSE-Controlled Human Mutant PS2 and APPsw
Hwang, D. Y., Cho, J. S., Oh, J. H., Shim, S. B., Jee, S. W., Lee, S. H., Seo, S. J., Song, C. W., Lee, S. H., & Kim, Y. K. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-005-4950-x · Cited by 6
Delayed amyloid plaque deposition and behavioral deficits in outcrossed AβPP/PS1 mice
Couch, B. A., Kerrisk, M. E., Kaufman, A. C., Nygaard, H. B., Strittmatter, S. M., & Koleske, A. J. (2012) · The Journal of Comparative Neurology · doi:10.1002/cne.23239 · Cited by 6
Cognitive Effects of Estrogen in Ovariectomized, Aged and Transgenic Mice Modeling Alzheimer's Disease
Heikkinen, T. (2006) · Cited by 6
Combination treatment with medium dose THC and CBD had no therapeutic effect in a transgenic mouse model for Alzheimer's disease but affected other domains including anxiety-related behaviours and object recognition memory
Aumer, B., Porto, R. R., Coles, M., Ulmer, N., Watt, G., Kielstein, H., & Karl, T. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174101 · Cited by 5
A combination of Δ9-tetrahydrocannabinol and cannabidiol modulates glutamate dynamics in the hippocampus of an animal model of Alzheimer's disease
Sánchez-Fernández, N., Gómez-Acero, L., Castañé, A., Adell, A., Campa, L., Bonaventura, J., Brito, V., Ginés, S., Queiróz, F., Silva, H. B. L., et al. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00439 · Cited by 5
Distinct disruptions in CA1 and CA3 place cell function in Alzheimer’s disease mice
Park, S., Park, M., Kim, E. J., Kim, J. J., Cho, J., & Huh, Y. (2025) · iScience · doi:10.1016/j.isci.2024.111631 · Cited by 5
Human Brain Banking as a Convergence Platform of Neuroscience and Neuropsychiatric Research
Liu, F., Yin, X., Cong, C., Wang, Y., & Ma, C. (2022) · Human Brain · doi:10.37819/hb.001.001.0204 · Cited by 5
Protein Degradation in Alzheimer’s Disease and Aging of the Brain
Tsuji, T., & Shimohama, S. (2002) · Progress in molecular and subcellular biology · doi:10.1007/978-3-642-56373-7_4 · Cited by 5
A transgenic mouse model for Alzheimer's disease has impaired synaptic gain but normal synaptic dynamics
Ricoy, U. M., Mao, P., Mańczak, M., Reddy, P. H., & Frerking, M. E. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.06.043 · Cited by 5
A Novel Way of Amelioration of Amyloid Beta Induced Toxicity in Caenorhabditis elegans
Saharia, K., Kumar, R., Gupta, K., Mishra, S., & Subramaniam, J. R. (2016) · Annals of Neurosciences · doi:10.1159/000449180 · Cited by 5
Classification of advanced methods for evaluating neurotoxicity
Han, K., & Woo, D. H. (2021) · Molecular & Cellular Toxicology · doi:10.1007/s13273-021-00161-6 · Cited by 5
Animal models in Alzheimer's disease: Biological plausibility and mood disorders
Castillo-Rangel, C., Marín, G., Díaz-Chiguer, D. L., Zarate-Calderon, C., Viveros-Martínez, I., Salazar, F., Torres-Pasillas, J. G., Hernández-Contreras, K. A., Vega-Quesada, L. A., Cano-Ortega, Y., et al. (2023) · Neurology Perspectives · doi:10.1016/j.neurop.2023.100110 · Cited by 5
Role of Alzheimer's disease models in designing and testing experimental therapeutics
Savonenko, A. V., Laird, F. M., Troncoso, J. C., Wong, P. C., & Price, D. L. (2005) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2005.11.006 · Cited by 5
Self-citation
Amyloid precursor protein and tau transgenic models of Alzheimer‘s disease: insights from the past and directions for the future
Sahara, N., & Lewis, J. M. (2010) · Future Neurology · doi:10.2217/fnl.10.10 · Cited by 5
Alzheimer transgenic models
Folkesson, R., Winblad, B. G., & Benedikz, E. (2002) · Current Opinion in Psychiatry · doi:10.1097/00001504-200207000-00015 · Cited by 5
The 3xTg-AD Mouse Model: Reproducing and Modulating Plaque and Tangle Pathology
Sy, M., Kitazawa, M., & LaFerla, F. M. (2010) · Neuromethods · doi:10.1007/978-1-60761-898-0_24 · Cited by 5
Animal and Translational Models of Neurological Disorders: An Industrial Perspective
Hunter, A. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00013-8 · Cited by 5
Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of anti‐amyloid therapies
Morgan, D., & Lamb, B. T. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13566 · Cited by 4
Amino Acid Transporters Proteins Involved in the Glutamate-Glutamine Cycle and Their Alterations in Murine Models of Alzheimer’s Disease
Vázquez-Durán, D. L., Ortega, A., & Rodríguez, A. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-03966-3 · Cited by 4
Motor activity in young APPswe + PS1/A246E bigenic mice as a predicting variable for memory decline
Filali, M., & Lalonde, R. (2015) · Journal of Neuroscience Research · doi:10.1002/jnr.23552 · Cited by 4
Histological and Behavioral Phenotypes of a Novel Mutated APP Knock-In Mouse
Plucińska, K., Crouch, B., Yeap, J., Stoppelkamp, S., Riedel, G., & Platt, B. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180336 · Cited by 4
TAPPing into the potential of inducible tau/APP transgenic mice
Xu, G. M., Ulm, B. S., Howard, J. C., Fromholt, S., Lü, Q., Lee, B. B., Walker, A. P., Borchelt, D., & Lewis, J. M. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12791 · Cited by 4
Self-citation
Chapter 5.5 Transgenic mouse models of Alzheimer's disease and episodic-like memory
Borchelt, D., & Savonenko, A. V. (2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(08)00230-0 · Cited by 4
Self-citation
The Role of HSP70 in the Protection of: (A) The Brain in Alzheimer’s Disease and (B) The Heart in Cardiac Surgery
Malyshev, I. Y. (2013) · SpringerBriefs in biochemistry and molecular biology · doi:10.1007/978-94-007-5943-5_8 · Cited by 4
Biologic models of neurodegenerative disorders
Eriksen, J. L., Zehr, C., & Lewis, J. M. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01216-x · Cited by 4
P1-227 Gene expression profiles of transcripts in amyloid precursor protein transgenic mice Up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease
Reddy, P. H., McWeeney, S. K., Park, B. S., Mańczak, M., Gutala, R. V., Jung, Y., Yau, V., Searles, R. P., Mori, M., & Joseph, Q. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80540-2 · Cited by 4
Chapter 3. β-Amyloid as a Target for Alzheimer's Disease Therapy
Augelli‐Szafran, C. E., Walker, L. C., & LeVine, H. (1999) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60565-5 · Cited by 4
Hippocampal structure and the action of cholinomimetic drugs
Csernansky, J. G., Bardgett, M. E., Dong, H., Humphrey, W. M., & Wang, L. (2002) · Drug Development Research · doi:10.1002/ddr.10106 · Cited by 4
Amyloidopathy in the Eye of Alzheimer′s Disease
Zhang, X. (2011) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.s5-005 · Cited by 3
Effects of resistance exercise on behavioral and molecular changes in transgenic female mice for Alzheimer's disease in early and advanced stages
da Silva, E. A., Faber, J., Penitente, A. R., Fernandes, J., Bertolucci, P. H. F., Longo, B. M., & Arida, R. M. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115217 · Cited by 3
A Question of Origins: Non-neuronal Sources of Amyloid-β
Sasmita, A. O., & Depp, C. (2026) · Neuroscience Bulletin · doi:10.1007/s12264-025-01572-4 · Cited by 4
Effects of Chronic 100 mg/kg Cannabidiol Treatment in Male Double Transgenic APPSwe/PS1∆E9 Mice
Watt, G., Olaya, J. C., Muench, G. W., Garner, B., & Karl, T. (2026) · Pharmaceuticals · doi:10.3390/ph19030374 · Cited by 3
Alzheimer's disease: Mechanisms and development of therapeutic strategies
Tabira, T. (2003) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1444-1586.2003.00082.x · Cited by 3
Alzheimer's Disease: Clinical Features, Neuropathologies and Biochemical Abnormalities, Genetics, Models, and Experimental Therapeutics
Price, D. L., Borchelt, D., & Wong, P. C. (2005) · Elsevier eBooks · doi:10.1016/b978-012738903-5/50028-x · Cited by 3
Self-citation
The presenilins as potential drug targets in Alzheimer’s disease
Cupers, P., Annaert, W. G., & Strooper, B. D. (1999) · Emerging Therapeutic Targets · doi:10.1517/14728222.3.3.413 · Cited by 3
Evolution and the scientific method
Tucker, H. M., & Estus, S. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00039-8 · Cited by 3
α7-Nicotinic Acetylcholine Receptors and β-Amyloid Peptides in Alzheimer’s Disease
Lorke, D. E., Petroianu, G. A., & Öz, M. (2016) · Neuromethods · doi:10.1007/978-1-4939-3768-4_10 · Cited by 3
Dynamics of Behavioral Disorders in Transgenic Mice with Modeled Alzheimer’s Disease
Семина, И. И., Байчурина, А. З., Makarova, E. A., Leushina, A. V., Kazakevich, Z. V., Gabdrakhmanova, M. R., Mukhamedyarov, M. A., & Zefirov, A. L. (2015) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-015-2821-0 · Cited by 3
Prion-like transmission of α-synuclein pathology in the context of an NFL null background
Rutherford, N. J., Brooks, M., Riffe, C. J., Gorion, K.-M. M., Howard, J. K., Dhillon, J.-K. S., & Giasson, B. I. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.09.054 · Cited by 3
Animal Models of Alzheimer's Disease
Bharadwaj, P. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch10 · Cited by 3
Beta Amyloid Protein Clearance and Microglial Activation
Frautschy, S. A., Cole, G. M., & Ard, M. D. (2002) · Springer eBooks · doi:10.1007/978-1-4757-4139-1_12 · Cited by 3
Lack of protective effect of estrogens on cerebral Aβ levels in intact female and male APP transgenic mice
Chakrabarti, E., Wang, J. P., Claire‐Olsen, J., & Smith, J. D. (2005) · Drug Development Research · doi:10.1002/ddr.20052 · Cited by 3
Animal models of dementia
Roberson, E. D., & Kao, A. W. (2016) · Cambridge University Press eBooks · doi:10.1017/9781139924771.007 · Cited by 3
Neuronal expression of S100B triggered by oligomeric Aβ peptide contributes to protection against cytoskeletal damage and synaptic loss
Saavedra, J., Nascimento, M., Figueira, A. J., da Silva, M. I. O., Gião, T., Oliveira, J. F., Liz, M. A., Gomes, C. M., & Cardoso, I. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1636365 · Cited by 2
Enhancing microglial antioxidant capacity via the ascorbate transporter SVCT2 delays onset and modifies disease progression in mouse models of Alzheimer's disease
Portugal, C. C., Santos, E. C. D. S., Monteiro-Pacheco, A., Pinto, S., Almeida, T. O., Tedim-Moreira, J., Gavin, D., Canedo, T., de Oliveira, F. S., Cardoso, I., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103851 · Cited by 2
Current Knowledge in Planarian Glia and Its Future Implications in Modeling Neurodegenerative Diseases
González, D., Alarcón, V., & Vásquez-Doorman, C. (2025) · Neuroglia · doi:10.3390/neuroglia6040037 · Cited by 2
Combining cannabidiol and delta-9-tetrahydrocannabinol at a 50:3 ratio – a new therapeutic strategy for APPSwe/PS1ΔE9 transgenic mice?
Coles, M., Porto, R. R., Chesworth, R., Steiner-Lim, G. Z., & Karl, T. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.04.003 · Cited by 2
Neuropathological and functional impact of astrocyte-derived extracellular vesicles in an aged model of Alzheimer's disease
Quach, B., Salehi, S. N., Roufegarinejad, R., Guleria, V. S., Mante, M., Florio, J. B., Rissman, R. A., & Winston, C. N. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115893 · Cited by 2
Cyclic Glycine-Proline Improves Memory and Reduces Amyloid Plaque Load in APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease
Arora, T., & Sharma, S. K. (2023) · International Journal of Alzheimer s Disease · doi:10.1155/2023/1753791 · Cited by 2
The Proof-of-Concept of MBA121, a Tacrine–Ferulic Acid Hybrid, for Alzheimer’s Disease Therapy
Rodríguez-Ruiz, E. R., Herrero-Labrador, R., Fernández-Fernández, A. P., Serrano, J., Martínez-Montero, J. A., González‐Nieto, D., Vaish, M., Benchekroun, M., Ismaïli, L., Marco‐Contelles, J., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512254 · Cited by 2
Cellular Adaptations to Intermittent Fasting with Emphasis on the Brain
Mattson, M. P. (2024) · Springer eBooks · doi:10.1007/978-3-031-49622-6_7 · Cited by 2
Striatal dopamine D2, adenosine A2A and cannabinoid CB1 receptors balance as a target against non-cognitive symptoms in a mouse model of Alzheimer's disease
Gómez-Acero, L., Sánchez-Fernández, N., Subirana, P., Ciruela, F., & Aso, E. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.173970 · Cited by 2
Biological Transgenic Mouse Models of Alzheimer's Disease
Crews, L. A., Rockenstein, E. M., & Masliah, E. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01227-4 · Cited by 2
Evaluación de la producción de b-amiloide por la mutación E280A en el gen de la presenilina 1
Villegas, A., Castañeda, M. M., Arias, L. F., Vieco, B., Lopera, F. J., & Bedoya, G. (2007) · Biomédica · doi:10.7705/biomedica.v27i3.200 · Cited by 2
Presenilin P264L knock-in mutation: Differential effects on abproduction, amyloid deposition, and neuronal vulnerability
Siman, R., Reaume, A. G., Savage, M. J., Scott, R. W., & Flood, D. G. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82329-5 · Cited by 2
Keystone Symposium, Neurodegenerative Diseases: New Molecular Mechanisms 17–22 February 2009
Fagan, T. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1100 · Cited by 2
Designing Animal Models of Alzheimer's Disease with Amyloid Precursor Protein (APP) Transgenes
Loring, J. F. (2003) · Humana Press eBooks · doi:10.1385/1-59259-195-7:249 · Cited by 2
Basic aspects in selecting a suitable transgenic rodent model for Alzheimer's disease.
Balmus, I. M., Ciobica, A. S., Negură, A., Negură, L., & Anton, E. (2015) · PubMed · Cited by 2
Preclinical models of Alzheimer’s disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy
Vasconcelos, B., Bird, M., Stancu, I., Terwel, D., & Dewachter, I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805120-7.00006-3 · Cited by 2
Crosstalk Signaling between IFN-γ and TGF-β in Microglia Restores the Defective β-amyloid Clearance Pathway in Aging Mice with Alzheimer's Disease
Choi, G.-E. (2018) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2018.24.4.305 · Cited by 2
Par-4 in Neuronal Death and Survival in Alzheimer’s Disease and Other Neurogenerative Diseases
Guo, Q., Xie, J., & Guo, C. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-80558-6_14 · Cited by 2
Animal models of Alzheimer’s Disease
Morgan, D. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0053 · Cited by 2
Behavioural Phenotyping to Study Cognitive and Non-cognitive Symptoms in the Rodent Model of Alzheimer’s Disease
Shivakumar, A. B., Mehak, S. F., Kumari, S., Saraf, V., & Gangadharan, G. (2022) · Springer eBooks · doi:10.1007/978-981-19-1352-5_14 · Cited by 2
Genetics of Alzheimer’s Disease and Related Disorders
Hardy, J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-661-4_1 · Cited by 2
Usefulness of Cerebrospinal Fluid Biomarkers in Diagnosis of Early Alzheimer's Disease
Herukka, S. (2007) · Cited by 2
Phospholipase D3 contributes to Alzheimer’s disease risk via disruption of Aβ clearance and microglia response to amyloid plaquesPreprint
Rosene, M. J., Hsu, S., You, S. F., Brase, L., Verbeck, A. C., Martinez, R. J., Wallace, C. E., Li, Z., Yan, P., Dräger, N. M., et al. (2022) · medRxiv · doi:10.1101/2022.01.31.22270175 · Cited by 2
Assessing effects of microwave electromagnetic field in APP/PS1 mice by in vivo GABA-weighted imaging via variable delay multipulse-chemical exchange saturation transfer MRI
Liu, S., Cheng, Y., Zhang, X., Shen, Y., Wu, S., Chen, Y., Shi, D., 庄彩玉, Chen, B., Zhong, Y., et al. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106131 · Cited by 1
Dual orexin receptor antagonism with lemborexant enhances microglial clearance of β-amyloid in mice
Sharma, A., 瀬川英美子, Chen, X., Park, S., Wang, S., Irmen, R. E., Constantino, N. J., Wang, C., Kanan, M. F., Colonna, M., et al. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00948-y · Cited by 1
Prospects for Neural Stem Cell Therapy of Alzheimer Disease
Gorba, T., Harper, S., & Mee, P. J. (2010) · Stem cell biology and regenerative medicine · doi:10.1007/978-1-60761-860-7_20 · Cited by 1
Neurodegenerative disorders
Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.030 · Cited by 1
The Molecular Basis of Alzheimer's Disease
Ingelsson, M., & Hyman, B. T. (2007) · Elsevier eBooks · doi:10.1016/b978-012369509-3.50018-4 · Cited by 1
Pathological Validation of Animal Models of Dementia
Pirici, D. N., Broeckhoven, C. V., & Kumar‐Singh, S. (2010) · Neuromethods · doi:10.1007/978-1-60761-898-0_7 · Cited by 1
The Biology of the Presenilin Complexes
Wakabayashi, T., Iwatsubo, T., & Strooper, B. D. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_3 · Cited by 1
Place cell physiology in a transgenic mouse model of Alzheimer's disease
Yi, M. (2009) · Cited by 1
Alzheimer Disease: Protein Misfolding, Model Systems, and Experimental Therapeutics
Price, D. L., Savonenko, A. V., Li, T., Lee, M. K., & Wong, P. C. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch12 · Cited by 1
Self-citation
AD‐Type Neuron Loss in Transgenic Mouse Models
Manaye, K. F., & Mouton, P. R. (2013) · Wiley eBooks · doi:10.1002/9781118444177.ch13 · Cited by 1
Mouse Models of Alzheimer's Disease
Oh, E. S., Lyketsos, C. G., & Wong, P. (2010) · Wiley eBooks · doi:10.1002/9780470669600.ch44 · Cited by 1
Pharmacological Models for Preclinical Testing: From Mouse to Dog to Nonhuman Primates
Eriksen, J. L., Murphy, M. P., & Head, E. (2010) · Wiley eBooks · doi:10.1002/9780470594087.ch7 · Cited by 1
LIPID SIGNALING IN BRAIN AGING AND ALZHEIMER'S DISEASE: PHARMACOLOGICALLY TARGETING CHOLESTEROL SYNTHESIS, TRANSPORT AND METABOLISM
Searcy, J. L. (2009) · UKnowledge (University of Kentucky) · Cited by 1
Mouse Models of Alzheimer’s Disease
German, D. C. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_16 · Cited by 1
Electron microscopist's view of the Alzheimer's plaque
Dikranian, K. T. (2012) · Biomedical Reviews · doi:10.14748/bmr.v23.25 · Cited by 1
Neuroprotective effects of Paeonia lactiflora and its active compound paeoniflorin against Aβ25-35-induced neurotoxicity in SH-SY5Y cells
Nam, M. N., Kim, J.-H., Lee, A. Y., & Cho, E. J. (2021) · Journal of Applied Biological Chemistry · doi:10.3839/jabc.2021.016 · Cited by 1

Authors: Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S.
Affiliations: Johns Hopkins University (US)
Frederick National Laboratory for Cancer Research (US)
Corresponding author: Borchelt, David R
ORCID: Borchelt, David R
Ratovitski, Tamara
Lee, Michael K
Jenkins, Nancy A
Sisodia, Sangram S
Venue: Neuron
Publisher: Elsevier BV
Published: 1997-10
Volume: 19
Issue: 4
Pages: 939-945
ISSN: 0896-6273 (ISSN-L)
DOI: 10.1016/s0896-6273(00)80974-5
OpenAlex: W2062214806
Cited by: 1,023
References: 52
Citations by year: 2026: 9 · 2025: 13 · 2024: 16 · 2023: 17 · 2022: 18 · 2021: 36 · 2020: 35 · 2019: 25 · 2018: 30 · 2017: 38 · 2016: 29 · 2015: 38 · 2014: 33 · 2013: 44 · 2012: 46
FWCI: 17.54
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1288 d)
Locations: Neuron (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: National Institute on Aging (AG 14248, P50AG005146, P01AG014248, AG 05146)
National Institute of Neurological Disorders and Stroke (NS-20471)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: presenilin 1, presenilin 2, amyloid precursor protein, familial Alzheimer's disease, amyloid-beta deposition, transgenic mice, amyloid-beta 42, amyloidosis, Alzheimer's disease pathogenesis
MeSH terms: Aging, Alzheimer Disease, Amyloid, Animals, Brain, Family, Humans, Membrane Proteins, Mice, Transgenic, Pedigree, Recombinant Fusion Proteins, Sweden, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Presenilin-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks